UK Cost-Effectiveness of Pegcetacoplan Compared with Ravulizumab for Treatment of Paroxysmal Nocturnal Haemoglobinuria - Supplementary materials.docx

Supplementary Table 1. Estimated utilities based on the Longworth and McKenzie algorithms 

Supplementary Table 2. Key scenario analyses

Supplementary Table 3. Probability of developing adverse events per cycle 

Supplementary Table 4. Iron overload disutility

Supplementary Table 5. Number of physician visits/tests per cycle1 and unit healthcare costs

Supplementary Table 6. Ravulizumab iron chelation costs

Supplementary Table 7. Intravascular haemolysis breakthrough cost for patients who discontinue pegcetacoplan due to intravascular haemolysis breakthrough

Supplementary Table 8. Unit costs of managing adverse events

Supplementary Table 9. OWSA results for the 10 parameters that contribute the largest difference to the NMB for pegcetacoplan versus ravulizumab